CTRI/2018/09/015704已完成未知
A multicenter, open label, balanced, randomized, two-treatment, two-period, two-sequence, two-way crossover, multiple dose, steady-state bioequivalence study of Risperidone Long-acting intramuscular injection of Qilu Pharmaceuticals Co. Ltd. with RISPERDAL CONSTA® (Risperidone) LONG-ACTING INJECTION of Janssen Pharmaceuticals, Inc. Titusville, NJ 08560 in patients with schizophrenia or bipolar I disorder.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Willing and able to provide voluntary informed consent and to follow the protocol requirements.
- •2.Patient aged 18-65 years (both inclusive) having Body Mass Index (BMI) between 17.00 and 30.00 (both inclusive) calculated as weight in kg/height in m2.
- •3.Patients with diagnosis of Schizophrenia or Bipolar I Disorder as per DSM-IV-TR criteria or later.
- •4.Patients receiving Risperidone long-acting injection at a dose of 25mg/vial via the intramuscular route and have completed at least 2 doses prior to randomization.
- •5.Acceptable hematology status:
- •a.Hemoglobin greater than or equal to 9 g/dL
- •b.Absolute neutrophil count (ANC) greater than or equal to 1500 cells/µL
- •c.Platelet count greater than or equal to 100,000 cells/µL
- •6.Acceptable liver function:
- •a.Alanine aminotransferase (ALT) less than or equal to 2X upper limit of normal (ULN)
- •b.Aspartate aminotransferase (AST) less than or equal to 2X ULN
- •c.Bilirubin less than 1.2 mg/dL
- •d.Alkaline phosphatase less than or equal to 2X ULN
- •7.Patients with Creatinine clearance greater than or equal to 60 mL/minute
- •8.Female patients with negative urine pregnancy test on admission day and serum pregnancy test at screening.
- •9.Females of child bearing potential must be willing to use adequate contraception (as defined below) throughout the study and continuing for at least 3 months after the last dose of the investigational product. For this study, acceptable and effective methods of contraception for females include:
- •a.Intrauterine device placed at least 3 months prior to the start of the study and remaining in place during the study period,
- •b.Two barrier methods used together (cervical cap, diaphragm, contraceptive sponge, or vaginal spermicide plus a male or female condom) or
- •c.Absolute sexual abstinence (no sexual intercourse or genital contact with a male partner).
- •10.For male patients, one of the following must apply in order to avoid impregnating a female partner, from the first study dose and agree to follow throughout the study and for at least 3 months following the last dose of the study.
- •a.Absolute sexual abstinence (no sexual intercourse or genital contact with a female partner).
- •b.Use of barrier method with spermicide
- •11.No history of addiction to any recreational drug or drug dependence or alcohol addiction.
排除标准
- •1.Hypersensitivity to Risperidone or Paliperidone or to any of the excipients.
- •2.Have current thoughts of suicide (suicidal ideation) or violent tendencies at the time of screening.
- •3.History or presence of neuroleptic malignant syndrome (NMS), tardive dyskinesia, dementia-related psychosis, Parkinsonâ??s disease or epilepsy/seizures.
- •4.Patients with positive urine screen for Drug of Abuse.
- •5.Patients who are on active treatment with drugs that are known to interact with risperidone (such as Strong CYP2D6 inhibitors, CYP3A4 enzyme inducers).
- •6.Smokers who smokes greater than or equal to 10 cigarettes or equivalent per day.
- •7.Patients on different antipsychotic treatment.
- •8.Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •9.Surgical or other non-healing wounds.
- •10.Patients with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
- •11.Uncontrolled diabetes mellitus.
- •12.An unusual or abnormal diet, for whatever reason planned e.g. religious fasting during the course of the study.
- •13.Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study that would limit adherence to study requirements.
- •14.Participation in any clinical study within 90 days before the first dose of Investigational Product.
- •15.Donation and/or loss of 350 mL (1 unit) of blood within 90 days prior to first dose of Investigational Product for the current study.
- •16.Patient is currently Pregnant or breastfeeding.
研究者
相似试验
已完成
不适用
A multicenter, open label, balanced, randomized, two-treatment, two- period, two-sequence, cross-over bioequivalence study of Pegylated Liposomal Doxorubicin HCl injection with that of Doxil® in ovarian cancer patients under fasting condition.CTRI/2014/08/004832Intas Pharmaceuticals Ltd48
进行中（未招募）
不适用
A multicenter, open label, balanced, randomized, two treatment, two-period crossover, multi-dose, steady state, bioequivalence study of Nevirapine 400 mg prolonged release tablets, compared to Viramune 400 mg prolonged release tablets in adult HIV1 infected patients.CTRI/2015/10/006244Amneal Pharmaceuticals Company GmbH
招募中
不适用
A multicenter, open label,patients with metastatic breast cancer patients under fed (standardized light meal) condition.CTRI/2022/06/043101TTY Biopharm Company Ltd
已完成
不适用
Bioequivalence study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Dr. Reddyâ??s Laboratories, with that of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Sun Pharmaceutical Ind., in ovarian cancer patientsCTRI/2014/06/004703Dr Reddys Laboratories Limited60
进行中（未招募）
不适用
Study of Paliperidone Palmitate injection 156mg/mL with INVEGA SUSTENNA® Injectable Suspension 156mg/mL in subjects with schizophrenia.CTRI/2020/05/025244Qilu Pharmaceutical Co Ltd